[
  {
    "ts": null,
    "headline": "Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=27486fe0d4189cad5c006d546f74c4206967fd958249de8af71a77ec8fc98435",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752250204,
      "headline": "Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?",
      "id": 135883913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=27486fe0d4189cad5c006d546f74c4206967fd958249de8af71a77ec8fc98435"
    }
  },
  {
    "ts": null,
    "headline": "InspireMD Launches CGuard Prime Carotid Stent System in the U.S.",
    "summary": "NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.",
    "url": "https://finnhub.io/api/news?id=bfb3eb87aa2bd926924e66d919e9cd54bef29eb124411eade967af24872420b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752242220,
      "headline": "InspireMD Launches CGuard Prime Carotid Stent System in the U.S.",
      "id": 135880919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.",
      "url": "https://finnhub.io/api/news?id=bfb3eb87aa2bd926924e66d919e9cd54bef29eb124411eade967af24872420b9"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Add Cencora Stock to Your Portfolio Now",
    "summary": "COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.",
    "url": "https://finnhub.io/api/news?id=ae8e744b7f289f2dc99898dc01c2692024cccedf72ae10dafa8e0c28087f8c9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752235320,
      "headline": "Here's Why You Should Add Cencora Stock to Your Portfolio Now",
      "id": 135880118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.",
      "url": "https://finnhub.io/api/news?id=ae8e744b7f289f2dc99898dc01c2692024cccedf72ae10dafa8e0c28087f8c9b"
    }
  }
]